Navigation Links
Extra Tests Not a Deterrent to Experimental Cancer Therapy
Date:3/4/2011

FRIDAY, March 4 (HealthDay News) -- Cancer patients are willing to tolerate multiple needle pokes, X-rays, ultrasounds, PET and CT scans to receive advanced experimental treatments in early-stage clinical trials, with some even amenable to extra tumor biopsies, according to a new study.

The finding from interviews with 61 patients with advanced cancer suggests a promising future for personalized medicine, in which doctors use specific treatments based on the genetic makeup of patients' tumors.

The study, conducted by researchers at the Mayo Clinic, Scottsdale Healthcare and the Translational Genomics Research Institute in Arizona, appears online and in the July 15 print issue of the journal Cancer.

"This is the first study of its kind where patients themselves were asked what tests and medical imaging studies they would be willing to undergo while participating in clinical studies for their cancer. Patients also were asked how invasive they perceived such tests and studies [to be]," lead author Dr. Raoul Tibes, a physician-scientist for the Mayo Clinic in Arizona, said in a Translational Genomics Research Institute news release.

To gain a better understanding about the molecular aspects of cancer, scientists need to collect tumor samples and analyze images from tests such as CT, MRI and PET scans.

"What we learned is that patients are, in general, very willing to undergo additional, extra tests to participate in clinical studies," Tibes said.

The patients said they were most willing to undergo urine, blood, ultrasound, X-ray, echocardiogram, PET and CAT scan tests. They were least willing to undergo tumor and skin biopsies and MRIs. However, most patients were willing to give one tumor biopsy sample per study, and sometimes two per study.

"This is important information, because it tells us that we can design clinical studies that ask patients to give extra tumor biopsies. But we need to carefully judge how many biopsies we request and what molecular tests we do with the tumor sample," senior study author Dr. Mitesh J. Borad, M.D., associate director of phase 1 drug development at the Mayo Clinic, said in the news release.

More information

The U.S. National Cancer Institute has more about personalized cancer care.

-- Robert Preidt

SOURCE: Translational Genomics Research Institute, news release, March 4, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Bitter melon extract attacks breast cancer cells
2. Bitter melon extract decreased breast cancer cell growth
3. Bitter Melon Extract May Slow, Stop Breast Cancer
4. Less Is More with the Innovation of Avemar(R) Fermented Wheat Germ Extract
5. Unique Equipment, Fun Workouts, Extraordinary Results
6. Green Tea Extract May Delay or Prevent Alzheimers
7. Tahitian Noni Extra Released With 16 Different Iridoids
8. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
9. Tahitian Noni Extra Sales Exceed Expectations
10. Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex
11. Human Extracellular Matrix Significantly Improves Device Biocompatibility
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Extra Tests Not a Deterrent to Experimental Cancer Therapy
(Date:6/28/2017)... Clara, CA (PRWEB) , ... June 28, 2017 , ... ... hosting a free AFM Luncheon for all SEMICONWest attendees and Park customers ... luncheon will feature talks from Dr. Sang-il Park, Chairman & CEO of Park Systems, ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... County and the surrounding regions access to insurance assistance and financial planning services, ... 25: Ministries to assist families in the region facing financial crisis. , Matthew ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel ... Mike Finnegan to the position of Executive Vice President, Sales and Marketing. Finnegan ... technology, telehealth and medical device sales leadership. He has received industry recognition for ...
(Date:6/27/2017)... ... 27, 2017 , ... Harbour , a DAO (decentralized autonomous organization) that ... has released their technical specifications . , 2017 has seen an explosion of ... for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... SUNucate efforts, Louisiana became the sixth state to pass legislation which ensures ... John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)...  Leaf Healthcare, recognized for developing one of ... ulcer prevention, will unveil its comprehensive mobility monitoring ... Nurses, National Teaching Institute and Critical Care Exposition ... Patient Monitoring System is the first mobility monitoring ... system seamlessly tracks patient movement throughout the mobility ...
(Date:5/22/2017)... May 22, 2017  As the specialty pharmacy ... continue to make the revolutionary shift from volume-based ... for ensuring positive patient outcomes and shaping the ... shifting focus away from clinical trials and toward ... long-term specialty drug therapy utilization in precise patient ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology: